- Lois et règlements
- eservices
-
Media Center
Hotline for Health Services for Displaced Lebanese 1787Hotline for the Patient Admission to Hospitals 01/832700COVID-19 Vaccine Registration Form covax.moph.gov.lbMoPH Hotline 1214
Are you a new member? Sign up now
close
VYZULTA - 0.024% - 5ml
| ATC | B/G | Ingredients | code | Registration Nb | brand_name | Dosage | Presentation | Form | Route | Agent | Laboratory | man_country | Price | Pharmacist Margin | Startum | Responsible Party Name | Responsible Party Country | Exch_date | %SUBSIDY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S01EE06 | B | Latanoprostene bunod - 0.024% | 10832 | 141920/1 | VYZULTA | 0.024% | 5ml | Solution | Ophtalmic | Spephal S.A.L. | Bausch and Lomb Incorporated | USA | 1,948,572 L.L | 23.08 | B | Bausch and Lomb Incorporated | USA | 2/5/2024 | 0 |